Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a smartphone app boost HIV prevention in drug users?

NCT ID NCT06068283

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a mobile app called LOTUS designed to help people who use drugs engage with HIV prevention services like testing and PrEP. The app provides tips, reminders, peer support, and a way to ask healthcare professionals questions. The trial will enroll 40 participants to see if the app is feasible, acceptable, and shows early signs of improving prevention service use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LOTUS mobile app (behavioral intervention)
What this could lead to
If it works, this could point toward a scalable way to improve HIV prevention among people who use drugs.
What could go wrong
This is a very small early trial (40 people) with no control group, so results may not be generalizable. The app may not be engaging enough to change behavior.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * Report weekly or daily use of opioids and/or stimulants in the past 6 months * Meet current CDC eligibility criteria for PrEP * Report low levels of HIV prevention service engagement in the past 6 months * Not currently, or planning on becoming, pregnant during the study * Owns a smartphone with internet web-browsing capabilities Exclusion Criteria: * 17 years of age or younger * Does not report weekly or daily use of opioids and/or stimulants in the past 6 months * Does not meet current CDC eligibility criteria for PrEP * Report high levels of HIV prevention service engagement in the past 6 months * Currently, or planning on becoming, pregnant during the study * Does not own a smartphone with internet web-browsing capabilities

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California San Diego

    La Jolla, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.